China's Third COVID-19 Vaccine Application... Phase 3 Clinical Trials with 40,000 Participants in 5 Countries

Conditional Approval Application for CanSino Biologics Following Sinopharm and Sinovac
Single Dose Severe Disease Prevention Effectiveness 94.47%

[Asia Economy Beijing=Special Correspondent Jo Young-shin] Chinese pharmaceutical company CanSino Biologics has applied to Chinese authorities for the general use of its COVID-19 vaccine.

According to China Securities Journal on the 24th, CanSino announced on the Hong Kong Stock Exchange that the National Medical Products Administration of China has accepted its conditional approval application for the recombinant COVID-19 vaccine (Ad5-nCoV) developed jointly with the Chinese Academy of Military Medical Sciences.

[Image source=Yonhap News]

Before CanSino, Sinopharm (China National Pharmaceutical Group) and Sinovac (Kexing Biology) had received approval for the use of inactivated vaccines.

CanSino disclosed that clinical trial results showed a protective efficacy of 68.83% against all symptoms 14 days after a single dose, with a severe disease prevention efficacy of 95.47%.

However, the efficacy somewhat declined over time, with protection against all symptoms at 65.28% and efficacy against severe disease at 90.7%.

CanSino stated that the vaccine’s protective efficacy met the technical standards of the World Health Organization (WHO) and the relevant requirements of China’s National Medical Products Administration.

The company said it conducted Phase 3 clinical trials in five countries including Pakistan, Mexico, Russia, Chile, and Argentina, completing vaccination of about 40,000 volunteers and related data analysis.

This content was produced with the assistance of AI translation services.